Hem › Psoriasisartrit › Ohio
Kliniska studier för Psoriasisartrit i Ohio
14 studier för Psoriasisartrit söker deltagare vid platser i Ohio.
Städer i Ohio
Officiell studietext (engelska)
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekryterarFas 3
Ålder 3 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT06663332A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
- Paramount Medical Research & Consulting, Middleburg Heights
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT07321873Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 23 sep. 2026 · NCT03816345A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- University Hospitals | UH Cleveland Medical Center - Department of Medicine - Rheumatology Division, Cleveland
- Paramount Medical Research & Consulting, LLC, Middleburg Heights
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 17 sep. 2026 · NCT06671483Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
- Clinical Site, Middleburg Heights
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 11 sep. 2026 · NCT06641089A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
- University Hospitals | UH Cleveland Medical Center - Department of Medicine - Rheumatology Division, Cleveland
- Paramount Medical Research & Consulting, LLC, Middleburg Heights
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 9 sep. 2026 · NCT06671496Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- Paramount Medical Research & Consulting, LLC, Middleburg Heights
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 9 sep. 2026 · NCT07286058A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- MetroHealth Medical Center /ID# 262377, Cleveland
- Cleveland Clinic - Cleveland /ID# 276655, Cleveland
RekryterarFas 3
Ålder 5 till 17 · Alla kön · Uppdaterad 1 sep. 2026 · NCT06100744Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
- Akron Children's Hospital, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Metrohealth Medical Center, Cleveland
- och 2 fler
RekryterarObservationsstudie
Upp till ålder 21 · Alla kön · Uppdaterad 27 aug. 2026 · NCT02418442A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
- Pa0019 144, Vandalia
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 6 juli 2026 · NCT07290036A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
- University Hospitals Cleveland Medical Center, Cleveland
RekryterarFas 4
Ålder 18 och äldre · Alla kön · Uppdaterad 3 apr. 2026 · NCT06454188Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
- Paramount Medical Research and Consulting /ID# 272757, Middleburg Heights
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 18 dec. 2025 · NCT06865105Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
- Cincy Arthritis, Blue Ash
- Southern Ohio Rheumatology, Wheelersburg
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 9 okt. 2025 · NCT05669833IMPACT - AndHealth Autoimmune Research Registry
- AndHealth, Columbus
RekryterarObservationsstudie
Ålder 18 till 70 · Alla kön · Uppdaterad 29 juni 2023 · NCT05883371Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.